Category Archives: Presentations

Silence Therapeutics CEO, Tony Sedgwick, was interviewed by Brr Media's Cameron Young over 3rd May 2012 announcement that Silence's agreement with partner Pfizer has been extended to develop one of its compounds containing Silence's AtuRNAi. A recording of the interview can be found here: http://www.brrmedia.com/event/97871/anthony-sedgwick-ceo

London, 21 March 2012 Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today announces its unaudited preliminary results for the year ended 31 December 2011.Tony Sedgwick, Chief Executive Officer of Silence Therapeutics, commented: In 2011 Silence Therapeutics has built a significantly stronger and more commercially-driven business. The...

Silence Therapeutics CEO Tony Segwick presented at the Bio-Europe Spring on20th March 2012 in Amsterdam, as part of companies presentations in the RNA Therapeutics/Gene Therapys section. More information companies presenting at the event can be found here: http://www.ebdgroup.com/bes/presenters/prs_comps.php 

Silence Therapeutics plc will be presenting at the upcoming Symposium on Nucleic Acids as Diagnostics and Therapeutics (Wednesday 14th of December 2011, Royal Society of Chemistry, Burlington House, London, UK). Dr. Klaus Giese will summarise the development of Atu027, Silences lead product which is currently in a Phase I clinical...

Silence Therapeutics CEO Tomas Christly presented at the Proactive Investors One2One Forum in London, alongside ANGLE, Deltex Medical and Stanley Gibbons on 23rd November 2011.Silence Therapeutics - Proactive Investors Presentation - November 23rd 2011 View more presentations from Silence TherapeuticsProactive Investors invited Silence Therapeutics to the event based on the...

Silence Therapeutics - 11th Annual Biotech Presentation View more presentations from Silence Therapeutics